Race Oncology Limited appoints George Clinical to support a Phase 1a/1b trial of RC220 Bisantrene in solid tumor patients.

Race Oncology Limited (ASX: RAC) announces that George Clinical International has been appointed as the Contract Research Organisation to support the clinical development of RC220 bisantrene. The selection of George Clinical followed a thorough process conducted by the Race Oncology clinical team. George Clinical is a leading global CRO with over 20 years of experience, conducting extensive trials globally and achieving a successful track record in conducting oncology trials at all phases in the United States, Europe, China, South-East Asia, New Zealand, and Australia.

In addition to their clinical trial expertise, George Clinical provides access to a network of influential clinical oncologists with extensive knowledge in treating solid tumors with anthracyclines. These clinical experts will collaborate with Race in optimizing and efficiently executing the proposed Phase I study of peripherally administered intravenous RC220 bisantrene in combination with a standard-of-care regimen of doxorubicin in patients with advanced solid tumors.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com